2nd Annual

WORLD IMMUNOTHERAPY CONGRESS 2017

31 Oct–2 Nov 2017 | Congress Centre, Basel, Switzerland

DISCOVER. DEVELOP. GET TO MARKET.



CO-LOCATED WITH

EUROPEAN ANTIBODY CONGRESS 2017

WORLD BIOSIMILAR CONGRESS EUROPE 2017

WORLD HPAPI CONGRESS 2017

CREATED BY

SPARK SOMETHING TERRAPINN

PARTNERED WITH

Basel

Want to get involved? Register your place today at **terrapinn.com/immunotherapy17**

WHAT IS THE EUROPEAN ANTIBODY CONGRESS AND WORLD IMMUNOTHERAPY CONGRESS?

The European Antibody Congress and the World Immunotherapy Congress are two commercially focused events that focus on the discovery, development, commercialisation and marketing of antibody therapeutics and immunotherapies.

Based in the life science hub of Basel, these two events look at commercialising and pushing forward the entire developmental pipelines of these therapies, as well as focusing on the hottest new individual therapeutics.

Over the last 12 years, the European Antibody Congress has built up a reputation for delivering high level content, and bringing together the top senior executives and thought leaders within the antibody space.

Launched last year, the World Immunotherapy Congress successfully brought together some of the top researchers working in big pharma, academia and biotech to talk about some of the hottest trends and therapeutics for 2016. 2017 will be looking at pushing the limits on cutting edge research and trials for one of the hottest therapeutics around.

NEW For 2017 we are introducing two new keynote sessions, and a new stream to the congress.

- We are introducing the "Strategies for Oncology" keynote panel, where executive representatives from big pharma are coming together to discuss strategies to tackle oncology, including a short presentation from each representative on the current 5-10-year strategical plan. Representatives from **Roche, GSK, Eli Lilly and Company, MSD** and **Pfizer** will participate.
- The day three keynote session will focus on **academic success and world leading research**. Four high level academics will each speak about their most recent, ground-breaking work presenting stories and data.
- A new stream, **"Moving from Phase III and Beyond"** will be focusing on the crucial steps after phase III trials, through regulatory approval, scale up and tech transfer, manufacture and commercialisation. This will give valuable insight on how to move your formats from bench to bedside.



TRACK CONTENT TO SUIT YOUR DAY-TO-DAY ROLE

Specific sessions on discovery, development, CMC and developability, target distribution, novel technology, mAbs, immune checkpoint inhibitors, cell therapy, combination therapy and novel discovery.

SCIENTIFIC POSTER SESSION

Discuss your work with experts during our poster session

PLATFORM TECHNOLOGY SHOWCASE

A targeted session exploring the most innovative new platform technologies being developed towards antibody engineering and development.

FANTASTIC NETWORKING

Over 700 of your peers in one room as well as the delegates of the co-locates World Biosimilar Congress and HPAPI World Congress.

Want to get involved? Register your place today at **terrapinn.com/antibody17**

WHAT'S NEW IN 2017?



EVEN MORE EXECUTIVE LEVEL BIG PHARMA AND BIOTECH

With over 80 senior representatives already confirmed from big pharma and biotechs in the speaking faculty alone, we can guarantee that you will have more opportunities to learn from and network with these key stakeholders. Meet C level directors and VPs from MSD, Pfizer, Roche, GSK, MedImmune, Affimed, Opsona Therapeutics, Pieris Pharmaceuticals, NantKwest, Unum Therapeutics, Crescendo Biologics, MacroGenics, Amgen, Bayer, Sanofi and more this Autumn.

EXPERT ACADEMIC AND REGULATORY INDIVIDUALS FROM LEADING INSTITUTIONS

This year we will hear from high level academics during the academic keynote, as well as representatives from the EPO and the FDA. Numerous academics will also take part in a panel discussion to talk about the current situation surrounding antibody INN.

EVEN MORE COVERAGE THROUGH MULTIPLE TRACKS

With 4 streams across the European Antibody Congress and the World Immunotherapy Congress, and with 200+ speakers across the entire combo, there will be more than enough content to satisfy even the most knowledge hungry attendees.

NEW STREAMS AND TOPICS

The European Antibody Congress this year will be launching a stream focusing on **phase III and beyond**, where we look at the stages a format must be taken through after clinical trials. This includes regulatory processes, scale up and tech transfer, manufacturing and commercialisation. We will also be focusing on **novel discovery within immunotherapies**, looking at new methods and processes.



MORE NETWORKING OPPORTUNITIES

With three days' worth of content, extended breaks and two drinks receptions, you will have even more time to meet contacts who will progress your projects and offer opportunities for collaboration.

Want to get involved? Register your place today at **terrapinn.com/antibody17**

THREE DAYS OF OPPORTUNITY

Through strategic keynote plenaries, themed tracks and dedicated networking sessions, you can really tailor the event to the needs of your day-to-day role.

True industry pioneers open the event sharing their expertise and ideas

EUROPEAN ANTIBODY CONGRESS 2017

Choose the content most valuable to your scientific needs

DAY 1	DAY 2	DAY 3
Opening keynote plenary session	Morning plenary keynote panel: Strategies for oncology	Morning plenary academic keynotes
Plenary roundtable session	Armed antibodies - Discovery / Bispecifics - Development / Platform Technology Showcase	Target distribution / Novel antibody technologies and future uses / mAbs
Speed networking		
Networking Lunch		
Armed antibodies - Discovery / Bispecifics - Development / Moving to phase III and beyond	Bispecifics - Discovery / Armed Antibodies - Development / CMC and developability	Target distribution / Novel antibody technologies and future uses / mAbs
Patents and antibody INN		Looking towards the future
Offsite networking drinks	Onsite networking drinks and poster viewing session	

WORLD IMMUNOTHERAPY CONGRESS 2017

DAY 1	DAY 2	DAY 3
Opening keynote plenary session	Morning plenary keynote panel: Strategies for oncology	Morning plenary academic keynotes
Plenary roundtable sessions	Cell Therapy	Combination therapy
Speed networking		
Networking Lunch		
Immune checkpoint inhibitors	Cell Therapy	Novel discovery and biomarkers
Offsite networking drinks	Onsite networking drinks and poster viewing session	Looking towards the future

Exhibition

1-2-1 Partnering

Use the online networking portal to browse the attendee list

An exhibition area that puts you in touch with industry-leading solution providers

Want to get involved? Register your place today at **terrapinn.com/antibody17**

Roy Baynes

Senior Vice President & Head, Global Clinical Development, Chief Medical Officer, **MSD**

Keynote: Anti PD-1 antibody therapy – a broad spectrum anticancer monotherapy and a backbone in combination therapy

- A biologically informed screening phase 2 program has identified broad spectrum monotherapy activity
- Pivotal trials have led to an expanding list of approved monotherapy indications
- Biomarker research is aimed at identifying those who benefit maximally from monotherapy and those who might be studied with biologically informed combination therapies
- An ever-expanding number of highly active combinations are being advanced

Puja Sapra

Executive Director,
Pfizer Worldwide Research and Development

Puja will be taking part in the "strategies for oncology" panel, and giving a short presentation on Pfizer's current oncology strategy.

She will also be giving an opening keynote presentation within the day 1 plenary session.

Michael DeRidder

Senior Director, Early Pipeline Commercial Strategy, Oncology Cell Therapy, **GSK**

Michael will be taking part in the "strategies for oncology" panel, and giving a short presentation on GSK's current oncology strategy.

Christian Rommel

Global Head of Oncology Discovery,
Roche

Christian will be taking part in the "strategies for oncology" panel, and giving a short presentation on Roche's current oncology strategy.

Sir Gregory Winter

Master of Trinity, **Cambridge University**
Founder and Co-Director, **Bicycle Therapeutics**

Keynote: Bicycles - a paradigm shift in pharmaceutical drugs?

- New platform based on repertoire technology
- Peptide conjugates with toxic drugs for treatment of cancer

Andreas Plückthun

Professor of Biochemistry, Director, Department of Biochemistry, **University of Zurich**

Keynote: Future Biologics: Exploiting the opportunities for protein engineering

- Future biologics need to open areas of application that expand on today's possibilities. This will be illustrated in several key areas
- The possibility of engineering geometry can be used to exert extremely strong effects on receptor signalling, such as a pan-HER inhibition

SPOTLIGHT ON SPEAKERS

EUROPEAN ANTIBODY CONGRESS 2017

WORLD IMMUNOTHERAPY CONGRESS 2017

Christoph Rader

Associate Professor, Department of Immunology and Microbiology, **The Scripps Research Institute**

Keynote: Cancer therapy with antibodies at the interface of biology and chemistry

- The presentation will encompass two strategies on covalently combining antibodies with small molecules to improve their scope and potency
- One strategy employs homogeneous antibody-drug conjugates that selectively deliver highly toxic small molecules to cancer cells without harming healthy cells
- The other strategy is based on chemically programmed bispecific antibodies that endow cancer-targeting small molecules with the power of cancer immunotherapy

M. Anthony Moody

Associate Professor, Department of Paediatrics, Division of Infectious Diseases, **Duke University Medical Centre**

Keynote: Immune regulation and the antibody response to HIV-1

- Many antibodies that have potent activity against HIV-1 have characteristics of autoantibodies
- Infected persons who make those antibodies have Immune system perturbations suggestive of dysregulation
- Understanding the relationship between immune dysregulation and HIV-1 antibody responses may help guide vaccine design

Michael Kalos

Chief Scientific Officer, ImmunoOncology, Lilly Research Laboratories, **Eli Lilly and CompanyMunich**

Keynote: Combination strategies in Immuno-oncology: the future is now

- First generation immunotherapies highlight the promise of harnessing the immune system to target cancer, but most patients do not receive durable benefit
- The complexity of the immune system and cancer interphase necessitates the development of combination therapies
- Development of rational combination therapies requires deep understanding of both the disease and the immunological landscape of patients

Andreas Hougaard Laustsen

Postdoctoral Fellow, Tropical Pharmacology Lab,
Technical University of Denmark

Keynote: Novel snakebite antivenoms based on oligoclonal recombinant antibodies

- Snakebite - the world's most neglected tropical disease
- The use of toxicovenomics (functional venom proteomics) to identify medically relevant snake venom toxins
- The use of phage display for discovery of human antibodies capable of neutralizing snake toxins
- Manufacturing perspectives for recombinant antivenoms

Janice Reichert

Executive Director, **The Antibody Society**
Editor-in-Chief, **mABs**

Keynote: Antibodies to watch in 2018

- A new record (14) for recombinant antibody products granted first marketing approvals may be set in 2017. These products, and those that might be granted approvals in 2018, will be identified.
- Antibody therapeutics in Phase 3 clinical studies will be discussed, and those likely to move to regulatory review in 2018 will be noted.
- New data on antibody therapeutics development metrics, including clinical phase transition and approval success rates, will be presented.

Alain Beck

Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

Alain will be chairing both the opening keynote and closing keynote session and will also be speaking on "Insights of multilevel state-of-the art analytical methods for antibody-based product structural assessment"

- Emerging 2D-LC-MS methods for mAbs and ADCs
- Orthogonal chromatographic and electrophoretic methods hyphenated to Mass Spec
- FDA/EMA approved mAbs and ADCs and 3G-ADCs case studies

Want to get involved? Register your place today at **terrapinn.com/antibody17**

"EAC REMAINS THE MOST DIVERSE AND INTERACTIVE ANTIBODY MEETING"

SENIOR DIRECTOR,
NBES ANALYTICAL CHEMISTRY

CENTRE D'IMMUNOLOGIE PIERRE FABRE
(EUROPEAN ANTIBODY CONGRESS 2017)

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 1 – TUESDAY 31 OCTOBER 2017

08:00 Registration opens

08:50 Conference doors open

08:55 Welcome from Terrapinn
Joan Shutt, Conference Manager, **European Antibody Congress, World Immunotherapy Congress 2017**

OPENING KEYNOTES: ANTIBODIES AND IMMUNOTHERAPY

09:00 Chair's opening remarks
Alain Beck, Senior Director, NBEs, **Pierre Fabre,** Associate Editor, **mAbs**

09:05 **Keynote: Combination strategies in immuno-oncology: the future is now**
- First generation immunotherapies highlight the promise of harnessing the immune system to target cancer, but most patients do not receive durable benefit
- The complexity of the immune system and cancer interphase necessitates the development of combination therapies
- Development of rational combination therapies requires deep understanding of both the disease and the immunological landscape of patients

Michael Kalos, Chief Scientific Officer, ImmunoOncology, Lilly Research Laboratories, **Eli Lilly and Company**

09:25 **Keynote: Anti PD-1 antibody therapy – a broad spectrum anticancer monotherapy and a backbone in combination therapy**
- A biologically informed screening phase 2 program has identified broad spectrum monotherapy activity
- Pivotal trials have led to an expanding list of approved monotherapy indications
- Biomarker research is aimed at identifying those who benefit maximally from monotherapy and those who might be studied with biologically informed combination therapies
- An ever expanding number of highly active combinations are being advanced

Roy Baynes, Senior Vice President & Head, Global Clinical Development, **Chief Medical Officer, MSD**

9:50 **Keynote: Combination therapies – the next frontier**
Puja Sapra, Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research, **Pfizer Worldwide Research and Development**

10:15 NETWORKING REFRESHMENT BREAK

11:35 **PLENARY ROUND TABLE DISCUSSION SESSION**
9 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.

TABLE 1
Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, pAbs
Alain Beck, Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

TABLE 2
Providing precision histopathology for discovery and development
Jeremy Clarke, Director of Commercial Development, **Asterand Biosciences & Lee Dawson,** Scientist, **Asterand Biosciences**

TABLE 3
Assessing off-target liabilities of biotherapeutics
Jim Freeth, Managing Director, **Retrogenix**

TABLE 4
Strategies for tackling cancer
Joern Schmitz, Head, Department of Immunotherapy, **Fraunhofer IME**

TABLE 5
Taking your formats to market
Speaker slot available

TABLE 6
Combination therapy
Speaker slot available

TABLE 7
Immunotherapy for solid tumours
Speaker slot available

TABLE 8
Biomarkers
Speaker slot available

TABLE 9
Preclinical models
Speaker slot available

12:20 **SPEED NETWORKING**
A fun, exciting and effective way to make a lot of initial connections
(in a very different environment from the standard business networking meetings).

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 1 – TUESDAY 31 OCTOBER 2017

12:35 — NETWORKING REFRESHMENT BREAK

DISCOVER – ARMED ANTIBODIES
EARLY DISCOVERY AND ANALYTICS

DEVELOP – BISPECIFICS
PRECLINICAL DEVELOPMENT

MOVING TO PHASE III AND BEYOND
Chaired by: **Michael Streit,** Senior Director, Clinical Leader Research, **Translational Medicine and Early Development, Oncology, Janssen**

14:10

Insights of multilevel state-of-the art analytical methods for antibody-based product structural assessment

- Emerging 2D-LC-MS methods for mAbs and ADCs
- Orthogonal chromatographic and electrophoretic methods hyphenated to Mass Spec
- FDA/EMA approved mAbs and ADCs and 3G-ADCs case studies

Alain Beck, Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

Insights into the molecular basis of a bispecific antibody's target and tumor-targeting selectivity

- Interplay of factors regulating target selectivity is not well understood and often overlooked when developing clinically relevant bispecific therapeutics
- We show that dual targeting alone is not sufficient to either promote efficient target selectivity or endow selective tumor-targeting
- The substantial roles played by the affinity of the individual arms, overall avidity and valence are described.

William Dall'Acqua, VP, Antibody Discovery and Protein Engineering, **Medimmune**

Lessons learned during the regulatory process of a recent marketing autorisation application

Achta Paraiso Le Bourhis, Associate Director, Global Regulatory CMC Lead, **Merck**

14:30

Protein LC-MS/MS applied for bioanalytics

- LC-MS/MS for large molecules offers orthogonality and complementary readouts to traditional ligand binding assays
- Hybrid LC-MS/MS as the answer to increasing demands in sensitivity?
- Case studies for pharmacokinetic, pharmacodynamic and immunogenicity studies (PK/PD/IG) by LC-MS/MS

Carsten Krantz, Investigator III, Drug Metabolism and Pharmacokinetics, **Novartis Pharma AG**

Bispecific antibodies mediate selective, safe and effective blockade of the immune checkpoint CD47

- Using Novimmune's κλ body platform, we have developed a series of bispecific antibodies with unbalanced affinities towards each target, that enable selective blockade of CD47 on tumor cells.
- Co-engagement of a tumor associated antigen and CD47 leads to superior tumor cell killing by macrophage in vitro and in vivo, leading to significantly increased efficacy in several animal models and to modification of the tumor micro-environment.
- For NI-1701, GMP manufacturing and preclinical package have been completed enabling entry into Phase I clinical trial for hematological malignancies.

Nicolas Fischer, Head of Research, **NovImmune SA**

Collaborations between big pharma and biotechs – running a format through phase III and commercialisation

- Innovative clinical development planning and implementation
- Regulatory strategies for first-in-class compounds
- Rationale combination strategies to expand and defend the approved asset

Michael Streit, Senior Director, Clinical Leader Research, Translational Medicine and Early Development, Oncology, **Janssen**

14:50

Using proteases as a new modality

Lutz Jermutus, Senior Director, R&D, **MedImmune**

Developing bispecific antibody therapeutics in immuno-oncology

- A bispecific antibody (mAb2) which can bind and block murine LAG-3 and PD-L1 with high affinity was engineered and characterised
- The anti-LAG-3/PD-L1 mAb2 inhibits LAG-3 and PD-L1 resulting in T cell activation in vitro
- In vivo efficacy demonstrated, where the mAb2 significantly decreased tumour burden in the MC38 and CT26 murine colon carcinoma models with comparable anti¬tumour activity to the antibodies given in combination

Biologics development in fast-evolving Chinese market – an industry perspective

- Biologics represent increasing share of the R&D pipeline for Chinese domestic and MNC pharma
- Innovative modalities and MOA are gaining attention from local investment
- Fast-evolving regulatory landscape and R&D infrastructure facilitate NBE and Biosimilar advancement

Yue Huang, Head of Clinical Pharmacology China, **Merck**

		• Preclinical data package supports developing an anti-human LAG-3/ PD-L1 mAb2 for the treatment of cancer **Mihriban Tuna,** Vice President, Drug Discovery, **F-Star**	
15:10	**Uncovering critical receptor targets and off-target binding using plasma membrane protein array technology** • A powerful approach to identify specific receptors for phenotypic antibodies and immune checkpoint ligands • Efficient off-target profiling of biotherapeutics including antibodies, ADCs, scFvs and whole CAR T cells **Alex Kelly,** European Business Development Executive, **Retrogenix**	**ATOR-1015, a bispecific immunomodulatory antibody targeting OX40 and CTLA-4** • Generation of ATOR-1015 – engineering of a stable bispecific immunomodulating bispecific antibody • Functional assessment of ATOR-1015 In vitro and in vivo • Drugability assessment of ATOR-1015 **Peter Ellmark,** Principal Scientist, Immuno-Oncology, **Alligator Bioscience**	**Fill and finish processing of biopharmaceutical manufacture** • Basic data acquisition focusing on the main physical chemistry properties of the drug product. • Preliminary calculations of process parameters based on prior knowledge using simulation tools in order to anticipate process parameters of freezing, thawing, mixing, filtration and filling parameters. • Set-up of Design space using Lab scale tests for each operation units in order to fine tune the calculation results. Thanks to preliminary calculations the number of experiments to be performed is reduced. • Set-up of robust and efficient scale-up that can leads to stable products in the monitored quality attributes **Mostafa Nakach,** Head of Pharmaceutical Engineering, **Sanofi**
15:30	NETWORKING BREAK		

REGULATIONS AND ANTIBODY INN

16:30	**FDA Update: Antibody therapeutics focusing on ADCs, bispecifics and cancer immunotherapies** • An update on regulation from the FDA focusing ADCs, bispecifics, cancer immunotherapies • What do the new biosimilar developments mean in terms of regulation considerations? • How does the regulation of new technologies such as T-Cells and immune checkpoints compare to that of regular mAbs? **Marjorie Shapiro,** Chief of Laboratory of Molecular and Developmental Immunology, **FDA – via weblink**
16:30	**Recent changes on EPO policy and insights into how to protect antibodies and related technologies** • Impact of the Early Certainty policy • The Unified Patent and the Unified Patent Court are they coming? • Requirement for clarification at the search stage • Broad claims in a crowded field **Helena Domingues,** Examiner, **European Patent Office**
17:10	**Patenting a strategically designed antibody-based portfolio in the United States** • Balancing claim scope with enablement and written description support • Obviousness in the U.S. versus Europe and the rest of the world • Lifecycle management for antibody-based inventions **Carla Mouta-Bellum,** Attorney, **Finnegan, Henderson, Farabow, Garrett & Dunner LLP**
17:30	**Panel: Antibody nomenclature and INN strategies** • Panel to discuss the current confusion surrounding antibody nomenclature • Why does the naming system have to be changed? • What problems are these causing in the clinic and the lab? • Suggestions on how this system can be improved **Moderator: Alain Beck, Head of Physico-Chemistry Department, Pierre Fabre, Associate Editor, mAbs** **Panellists:** **Hervé Watier,** Co-ordinator of the MAbImprove LabEx, **University of Tours** **Stefan Dübel,** Director, Department of Biotechnology, **Technnische Universität Braunschweig**
18:10	OFFSITE NETWORKING DRINKS

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 2 – WEDNESDAY 1 NOVEMBER 2017

08:00 Registration opens

08:50 Conference doors open

STRATEGIES FOR ONCOLOGY

09:00 Chair's opening remarks
Alain Vertes, Managing Director, **NxR Biotechnologies**

09:05 **Panel: Oncology strategies across pharma**

- High level pharma companies come together to discuss their strategies for tackling cancer
- Each company will give a 5-minute presentation on their strategy, and a fire side discussion on oncology focused strategies will follow
- Strategies will cover cytotherapy, checkpoint inhibitors, combination therapy, sequential therapy, approaches to solid tumours, treatments and diagnostics

Moderator: Alain Vertes, Managing Director, **NxR Biotechnologies**
Michael DeRidder, Senior Director, Early Pipeline Commercial Strategy, **Oncology Cell Therapy, GSK**
Christian Rommel, Global Head of Oncology Discovery, **Roche**
Puja Sapra, Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research, **Pfizer Worldwide Research and Development**
Roy Baynes, Senior Vice President & Head, Global Clinical Development, Chief Medical Officer, **MSD**
Michael Kalos, Chief Scientific Officer, ImmunoOncology, Lilly Research Laboratories, **Eli Lilly and Company**

10:25 NETWORKING BREAK

DISCOVER – ARMED ANTIBODIES
TARGET DISCOVERY AND BIOMARKERS

11:25 **Small is beautiful – Humabodies Drug Conjugates, HDC's a real alternative to ADC's**

- Crescendo is developing a pipeline of novel multifunctional Humabody® therapeutics demonstrating excitingly differentiated efficacy compared with clinical mAbs
- Optimally configured Humabody Drug Conjugates (HDCs) engage therapeutically valuable targets in a way that is different from whole antibodies, unlocking superior therapeutic index
- Highly potent HDCs will play an important role in the next generation of targeted oncology therapeutics as a critical component of increasingly effective combination regimes

Thomas Sandal, VP R&D, **Crescendo Biologics**

DEVELOP – BISPECIFICS
PRECLINICAL DEVELOPMENT

Engineering an Affibody® fusion protein trap towards therapeutic blocking of IL-17 in man

- Psoriasis is an IL-17 driven disease.
- An Affibody® based 18.6 kDa ligand trap was engineered to block IL-17A with femtomolar affinity
- The trivalent bispecific fusion protein blocks IL-17 with unparalleled affinity and displays long plasma half-life as shown in man
- Early development and data from Phase I/II will be presented

Joachim Feldwisch, Director of Preclinical Development, **Affibody AB**

PLATFORM TECHNOLOGY SHOWCASE
Chaired by: **Ulf Grawunder,** CEO, **NBE Therapeutics**

A better way to characterize monoclonal antibodies with prometheus

- Understanding the biophysical properties of monoclonal antibodies can provide powerful insights into screening and characterizing this important class of biologics.
- Nanotemper-Technologies' Prometheus platform which performs nano-Differential Scanning Fluorimetry (nanoDSF), a method that provides flexible analysis and ultra-high resolution of protein stability and aggregation will be discussed
- Utilization of thermal and chemical unfolding as well as aggregation data on monoclonal antibodies can be used as predictive indicators in formulation and stability studies, ultimately resulting in improved biotherapeutic products.

Christian Kleusch, Application Scientist Biophysics, **Nanotemper**

Want to get involved? Register your place today at **terrapinn.com/antibody17**
See the website for the most up to date agenda

11:45

A novel antibody drug conjugate targeting the Trypanosoma brucei haptoglobin-haemoglobin receptor to treat sleeping sickness

- Taking advantage of receptor-mediated nutrient uptake by trypanosomes, toxin-conjugated monoclonal antibodies recognising these receptors could be used to target and deliver a toxin to the parasite The T. b. brucei haptoglobin-haemoglobin receptor
- Monoclonal antibodies generated against the HpHbR N-terminal were conjugated to Pyrrolobenzodiazepine (PBD) toxins leading to targeted cell killing of trypanosomes at picomolar concentrations

Andrea Gonzalez-Munoz, Research Associate, **MedImmune**

Senior Representative, MaxCyte

Exceptional human antibody discovery with a best-in-class transgenic mouse

- Examine a unique transgenic platform: expression of a complete human antibody variable domain repertoire drive by optimized murine genetic sequence – The Trianni Mouse.
- Review licensee case studies and internal validation data
- Learn about future strains and modifications under development

David Meininger, Chief Business Officer, **Trianni**

12:05

A smart microfluidic technology for early discovery and analytics

- A new "intelligent" LabChip microfluidic platform for high throughput quantitation and quality screening of protein products
- Intelligent System Technology method utilizes a microchip which utilizes real-time electro-hydrodynamic optimization to eliminate variability in reported results
- Using the Labchip system one can attain high reproducibility of samples, greater accuracy and sensitivity. The intelligent microfluidic platform is designed to address future of protein product development and downstream production processes in biopharmaceutical industry

Anubhav Tripathi, Professor of Bioengineering and Medical Science, **Brown University**

DEVELOP - BISPECIFICS
CLINICAL DEVELOPMENT

Senior Representative, CMC Biologics

A unique source of therapeutic antibodies with one of the industry's most versatile technology platforms

Volker Lang, Managing Director, **AbCheck**

12:25

Novel DART and TRIDENT molecules with unique modes of action

- Advancing half-life extended DART molecules for redirected T-cell killing
- Strategies to target checkpoint and costimulatory pathways
- Adapting TRIDENT protein's avidity and valency to address diverse modes of action

Syd Johnson, VP, Antibody Engineering, **MacroGenics**

Advancing DART molecules in the clinic

- Translating pre-clinical information in the clinic
- Early clinical pharmacodynamic
- Preliminary clinical experience

Ezio Bonvini, SVP & CSO, Research, **Macrogenics**

ProTIA – Bispecific T cell engagers designed for local activation by tumor-associated proteases

- A new "intelligent" LabChip microfluidic platform for high throughput quantitation and quality screening of protein products
- Intelligent System Technology method utilizes a microchip which utilizes real-time electro-hydrodynamic optimization to eliminate variability in reported results
- Using the Labchip system one can attain high reproducibility of samples, greater accuracy and sensitivity. The intelligent microfluidic platform is designed to address future of protein product development and downstream production processes in biopharmaceutical industry

Volker Schellenberger, President and CEO, **Amunix**

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 2 – WEDNESDAY 1 NOVEMBER 2017

13:05 NETWORKING LUNCH

14:35

Target discovery using sugars
Andre Choo, Principal Scientist and Director, Antibody Discovery, Bioprocessing Technology Institute, **A*STAR**

Bstrongximab, a novel antibody-drug-conjugate targeting metastatic cancer

- Embryonic antigens expressed in cancers but not normal tissues offer a new class of cancer targets for development of antibody-drug-conjugates
- Bstrongximab is a human chimeric antibody-drug-conjugate with high affinity and specificity to a novel embryonic cancer target expressed in colon, gastric, pancreatic and esophageal cancers
- In vitro and in vivo preclinical data show Bstrongximab to be a highly specific and potent cancer antibody-drug-conjugate

Michael Schopperle, Chief Executive Officer, **CureMeta**

CMC AND DEVELOPABILITY

Integrating novel tools into development workflow of antibodies: nanoDSF and MST for discovery, development and QC

- Biophysical approaches are routinely used to assess biologics activities, stability and quality
- Modern drug discovery operations require characterization of biomolecular interactions to be both time- and cost-effective as well as to be highly precise and reproducible
- Here we report applications of two novel methods nano-Diffrential Scanning Fluorimetry (nanoDSF) and MicroScale Thermophoresis (MST) that we are applying in our biologics discovery and characterization operations
- The examples of the demonstrated effectiveness of the nanoDSF and MST will be presented and discussed

Alexey Rak, Head of Bio Structure and Biophysics, **Sanofi R&D**

14:55

DISCOVER – BISPECIFICS
EARLY DISCOVERY AND ANALYTICS

Bi-Specific Antibodies: Discovery and Engineering

- Strategies and challenges associated with bi-specific antibody discovery
- Engineering strategies and formats for bi-specific antibodies
- Challenges associated with production of bi-specific modalities

John Delaney, Executive Director, **Amgen Biologics Discovery**

DEVELOP - ARMED ANTIBODIES
PRECLINICAL DEVELOPMENT

Preclinical modeling and screening strategies to improve the clinical translation of ADCs

- How to avoid common pitfalls in misinterpreting preclinical data
- Best practices in establishing a predictive therapeutic index

Scott Dylla, CSO, **Abbvie Stemcentrx**

Senior Representative, Fujifilm Diosynth Biotechnologies UK

15:15

nformation content and molecular complexity: how important are the size and design of libraries?

- Selections for HIV-1 entry inhibitors used a variety of libraries
- We analyzed the winning sequences, to determine how the library design may have dictated their emergence
- The role of library design and library size will be examined
- Results may lead to a deeper understanding of how to set up successful selections

Jonathan Davis, Principal Scientist, Molecular Structure and Design, **Bristol-Myers Squibb**

Bringing PBD-ADCs to the clinic

- Introduction to PBDs
- Preclinical data on ADCs targeting CD19, CD25, CD22 and HER2
- Translation to the clinic : PBD PD biomarkers
- Clinical validation: Current landscape of advanced PBD-ADCs
- Clinical plans and current status of the ADC-Therapeutics pipeline

Jens Wuerthner, Assistant Vice President, Head of Clinical Development – EU, **ADC Therapeutics**

The production of a novel scFv against coeliac disease – from gene to final product

- Introduction to coeliac disease and a novel scFV for treatment
- Overview of the scFV inclusion body process and challenges therewith
- Integrated Bioprocessing – how does one Unit Operation influence the other in the scFV IB process?
- Is the final product useful and competitive to available treatment?

Oliver Spadiut, Assistant Professor, Integrated Bioprocess Development, **TU Wien**

Want to get involved? Register your place today at **terrapinn.com/antibody17**
See the website for the most up to date agenda

15:35

Automated optimization of IgG production in CHO cell line development in high-throughput modus

- The goal of cell line development is high quantities of a protein of interest
- Utilizing a factorial design of experiment conditions improved antibody titer by 42-66%
- Fully automated setup of media conditions, cell plating, and assay preparation followed by IgG titer measurement will be reported
- Ease of sample preparation and rapid processing qualify Bio-Layer Interferometry (BLI) based systems for higher throughput applications such as expression clone screening

Lisette Bronswijk, Application Scientist Manager EMEA, **PALL ForteBio**

Preclinical validation of site-specifically conjugated ADCs with potent anthracycline payloads in solid and hematologic tumor models

- Validation of a novel ultrapotent anthracycline-toxin in ADCs
- Preclinical validation of NBE's lead ADCs in preclinical tumor models
- Characterization of the immune-oncology function of NBE's ADCs

Ulf Grawunder, CEO, **NBE Therapeutics**

The road to the clinic – a CDMO perspective

- How early is early enough – considerations for cell line development
- Titers vs. Critical Quality Attributes – are high titers really better?
- Developability and the need to develop a robust process that will transfer into manufacturing
- Analytics, Analytics, Analytics

Stewart McNaull, Senior VP, Business Development, **KBI Biopharma**

15:55 NETWORKING BREAK

17:00

Analysis of therapeutic molecules by high resolution and native mass spectrometry

- Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry
- Quantitative determination of protein-ligand affinity by online SEC high-resolution native mass spectrometry

Guanghui Han, Scientific Manager, **Genentech**

DEVELOP - ARMED ANTIBODIES
PRECLINICAL DEVELOPMENT

Payload considerations for IMGN632, a CD123-targeting ADC for acute myeloid leukemia

- IMGN632 is a novel ADC linking an anti-CD123 antibody with ImmunoGen's DGN549 payload via site-specific Cysmab technology
- DGN549 is a DNA alkylator, as opposed to a DNA cross-linker
- IMGN632 selectively kills AML cells over normal myeloid progenitors

Thomas Keating, Senior Director, Biochemistry, **Immunogen**

An integrated approach to assess the developability of biologics

- Developability assessment of Biologics: how to select the winners
- Immunogenicity risk assessment
- State-of-the art cell line development

Steffen Hartmann, Global Head Integrated Biologics Profiling, **Novartis**

17:20

DISCOVER - BISPECIFICS
TARGET DISCOVERY AND BIOMARKERS

Targeted bispecific for progressive renal diseases

- Improving therapeutic potential of renoprotective agents by increasing drug concentrations to target tissues and limiting systemic exposure
- A case study using an acute model of fibrosis will be presented
- Will discuss about identification and validation of new epitopes differentially expressed in diseased tissue for bispecific targeting approaches

Ivan Mascanfroni, Senior Scientist, Immunology Biologics, **AbbVie Bioresearch Centre**

De-risking the route of ADCs to the clinic

- Novel target selection
- Exploratory toxicology
- Payloads with better tolerability
- Dosing for a therapeutic window

Robert Boyd, Scientific Director, **Oxford BioTherapeutics UK**

Assessing mAb's CMC related properties during early lead discovery stage by using endoplasmic reticulum as a physiological test tube

- Depending on the properties embedded in the VL and VH regions, some mAbs show undesirable condensation propensity at high protein concentrations
- Condensation-prone IgG mAbs can induce three different prominent cellular phenotypes during overexpression in mammalian cells
- This talk will illustrate the predictive values of overexpression-induced cellular phenotypes in assessing the solution behaviors of individual mAb clones

Haruki Hasegawa, Principal Scientist, Department of Therapeutic Discovery, **Amgen**

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 2 – WEDNESDAY 1 NOVEMBER 2017

17:40	**Anti-cytokine therapies for inflammatory diseases** • Selection of the most promising targets • Which approaches are likely to be successful and which not? **Jiri Kovarik,** Senior Research Investigator, **Novartis Institutes for Biomedical Research**		**CHOptimizer: Platform approach to fast and efficient titer and process improvement via CHO media optimization** • A flexible and transparent media optimization service with the ambr® 15 microbioreactor system • Case study examples of improved fed-batch processes producing a variety of antibodies • An integrated platform approach driving improvement in peak viable cell density and titer adjusted to the individual manufacturing set-up **Andreas Wiesner,** Global Product Manager, Cell Culture Media, **Sartorius Stedim Biotech**
18:00	**A novel heterodimerization strategy as plattform for mono- and multispecific drug candidates** • Principles of the novel heterodimerization strategy • Generation of a lead candidate as platform module • Examples for further applications **Fabian Richter,** Post-Doc, **University of Stuttgart**		**Developability: looking for "drug like properties" right from the start** • How to address developability early on in lead discovery • In silico and higher throughput in vitro methods • Developability in LO Phase and specialties for ADCs **Lars Linden,** Head of Protein Biochemistry, **Bayer AG**
18:20	Chair's closing remarks	Chair's closing remarks	Chair's closing remarks
18:30	POSTER PRESENTATION SESSION Posters allow for pharma, biotech and academia to present previously unpublished work. Taking place during the networking drinks on day two of the congress, it will be possible for poster contributors to answer questions and gain feedback.		

Want to get involved? Register your place today at **terrapinn.com/antibody17**
See the website for the most up to date agenda

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 3 – THURSDAY 2 NOVEMBER 2017

08:00 Registration opens

08:50 Conference doors open

STRATEGIES FOR ONCOLOGY

09:00 Chair's opening remarks

09:05

Keynote: Bicycles - a paradigm shift in pharmaceutical drugs?

- New platform based on repertoire technology
- Peptide conjugates with toxic drugs for treatment of cancer

Sir Gregory Winter, Master of Trinity, Cambridge University, Founder and Co-Director, **Bicycle Therapeutics**

09:30

Keynote: Future Biologics: Exploiting the opportunities for protein engineering

- The possibility of engineering geometry can be used to exert extremely strong effects on receptor signalling, such as a pan-HER inhibition
- Intracellular targets may gradually come within reach. Using systems inspired by engineered bacterial toxins (3), levels can now be reached which are much higher than with positively charged peptides, and more importantly, allow cell-specific uptake
- Viral delivery may open new avenues to administer cocktails of therapeutic proteins in a localized manner, not by creating replication-proficient "oncolytic" viruses, but instead by engineering viruses, able to target predesigned cell types (5), which can be used to produce therapeutic proteins in vivo, at locations where they are needed

Andreas Plückthun, Professor of Biochemistry, Director, Department of Biochemistry, **University of Zurich**

09:55

Keynote: Cancer therapy with antibodies at the interface of biology and chemistry

- The presentation will encompass two strategies on covalently combining antibodies with small molecules to improve their scope and potency
- One strategy employs homogeneous antibody-drug conjugates that selectively deliver highly toxic small molecules to cancer cells without harming healthy cells
- The other strategy is based on chemically programmed bispecific antibodies that endow cancer-targeting small molecules with the power of cancer immunotherapy

Christoph Rader, Associate Professor, Department of Immunology and Microbiology, **The Scripps Research Institute**

10:20

Keynote: Immune regulation and the antibody response to HIV-1

- Many antibodies that have potent activity against HIV-1 have characteristics of autoantibodies
- Infected persons who make those antibodies have Immune system perturbations suggestive of dysregulation
- Understanding the relationship between immune dysregulation and HIV-1 antibody responses may help guide vaccine design

M. Anthony Moody, Associate Professor, Department of Paediatrics, Division of Infectious Diseases, **Duke University Medical Centre**

10:45 NETWORKING BREAK

TARGET DISTRIBUTION	NOVEL ANTIBODY TECHNOLOGIES AND FUTURE USES	MABS
11:45		
Antibody therapeutics for CNS diseases and their delivery across the BBB • We have used our antibody engineering platform to develop a fully human monoclonal antibody that crosses the blood brain barrier and an antibody that blocks the ligand gated ion channel P2X4 • We have confirmed central penetration and PK of the BBB antibody in vivo • We have utilised a model of neuropathic pain to confirm activity of the P2X4 antibody in a bi-specific construct with the BBB antibody **Carl Webster,** Principal Scientist, Antibody Discovery and Protein Engineering, **MedImmune**	**Universal affinity switches for antibodies** • Allosteric affinity modulation module for scFv antibodies • Demonstrated to switch 5 different antibodies • Works both for Vl-Vh and Vh-Vl scFv • Works at physiological milieu (no ph / ion changes necessary) **Stefan Dübel,** Director, Department of Biotechnology, **Technnische Universität Braunschweig**	**Targeting netrin-1: from preventing cancer stemness to strengthening immunotherapy** • Overview on dependence receptors • The pairs netrin-1/netrin-1 receptors (DCC, UNC5B) are the prototypical ligand/dependence receptors pairs • An anti-netrin-1 mAb called NP137 has been preclinically developed and is currently assessed in a first-in-man-first-in-class phase I clinical trial • The NP137 shows preclinical efficacy related to a specific effect on cancer stem cells. • Preclinical data support the importance of combining NP137 with immune-checkpoint inhibitors. **Patrick Mehlen,** Director of Translational Research, Centre Léon Bérard, Chief Executive Officer, **Netris Pharma**

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 3 – THURSDAY 2 NOVEMBER 2017

12:05

Optimizing delivery of antibodies across the BBB via the Transferrin Receptor and other novel transporters

- We have developed second generation single domain VNARs for efficient transfer of antibodies across the BBB
- Using a combined in Vitro and in Vivo phage display screening paradigm we have isolated VNARs to the transferrin receptor that give brain /plasma ratios of up to 10% at 20 hours with clear parenchymal staining
- Mutagenesis of the VNAR CRD3 region has identified key residues essential for transfer and allowed additional optimization
- New non TfR VNARs have been isolated from in Vivo phage display with highly efficient transfer. Current efforts are designed to identify the molecular targets

Frank Walsh, CEO, **Ossianix**

Antibodies to post translationally modified auto-antigens as biomarker for early diagnosis of disease

- Link between metabolism and autoimmunity
- Formation of neoantigen at early stages of autoimmune diseases
- Examples from arthritic conditions and Type 1 autoimmune diabetes

Ahuva Nissim, Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology, William Harvey Research Institute, **Queen Mary University**

Discovering and engineering antibodies by high-throughput repertoire sequencing

- Computational and experimental methods in antibody repertoire sequencing
- Comprehensive error and bias correction method that enables highly accurate sequencing
- Applying machine-learning approaches that enable prediction of the immune status
- Use of genome editing and mammalian cells to screen antibody repertoires

Sai Reddy, Assistant Professor, Biomolecular Engineering, **ETH Zurich**

12:25

Blood-Brain Barrier Penetrating Dual Specific Binding Proteins for Treating Brain and Neurological Diseases

- Will describe the generation and expression of DVD-Ig proteins which are capable of binding specific disease targets in the brain.
- The brain uptake and retention, following an systemic administration, as well as the elevated functional activity of DVD-Ig proteins will be demonstrated.

Katherine (Kangwen) Deng, Senior Scientist, **AbbVie Bioresearch Centre**

Novel microbial fermentation technology for production of antibodies

- Cost and time efficient development of microbial fermentation
- Controlled regulation of expression yields in E. coli
- Case study: E. coli as platform for production of functional antibody fragments

Sagrario Arias Rivas, Principal Scientist and Project Manager, **Batavia Biosciences**

Anti-stem monoclonal antibodies against Influenza

- Neutralization and ADCC are the mechanisms of broadly cross-reactive protection provided by monoclonal antibodies against the stem region of Influenza HA antigens
- Stem directed monoclonal antibodies protect broadly protect in the mouse and ferit against influenza challenge
- Human influenza challenge studies demonstrate that higher levels of these monoclonal antibodies are required in the nasopharynx for protection than can practically by achieved by intramuscular injection
- Active vaccines have been designed based on the epitopes identified by these monoclonal antibodies that can elicit broad neutralizing antibody, ADCC and protection in the mouse lung

Jerald Sadoff, Senior Advisor Vaccine Development, Senior Clinical Advisor RSV, **Janssen Infectious Diseases and Vaccines**

12:45

Liver targeted insulin

- Design and generation of an antibody based liver biased insulin analog
- The construct showed enhanced insulin activity on hepatocytes in vitro
- The construct demonstrated liver biased distribution and PD effect in rats

Feng Wang, Principal Investigator, Biology, **CaliBR**

Droplet microfluidics – antibody discovery and vaccine development at very high throughput

- Droplet based microfluidics for the direct screening and sequencing of millions of primary murine (from spleen and bone marrow) and human (from blood) plasma cells
- Assays for antibody binding, inhibition of enzymatic drug targets, effect on target cells
- Compatible with difficult targets such as GPCRs
- Complementary platform for the development of vaccine candidates based on massively parallelized single-virus assays

Christoph Merten, Group Leader Microfluidics, **European Molecular Biology Laboratory**

LY2624587, a clinically tested anti-CXCR4 antibody induced apoptosis of hematologic malignancies

- Overexpression of CXCR4, a receptor for the chemokine CXCL12 (SDF-1), is a hallmark of many haematological malignancies including acute myeloid leukaemia, chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and generally correlates with a poor prognosis.
- We developed and advanced into the clinic, a potent anti-CXCR4 monoclonal antagonist antibody, LY2624587, for treatment of cancer
- LY2624587 blocked SDF-1 binding to CXCR4 and inhibited SDF-1 induced cell migration and downstream cell signalling
- In human hematologic cancer cells, LY2624587 caused dose dependent apoptosis in vitro and in vivo

Victor Obungu, Principal Research Scientist, **Eli Lilly and Company**

13:05

Recombinant antibody brain shuttles - Improved immunotherapy and diagnostics of neurodegenerative diseases

- We have generated a shuttle that transports antibodies across the BBB
- It is bivalent but binds monovalently to the TfR dimer
- We have used it to improve antibodies in both diagnostics and therapeutics of neurodegenerative diseases

Greta Hultqvist, Department of Public Health and Caring Sciences, **Uppsala University**

IMGT/HighV-QUEST for NGS scFV analysis from antibody combinatorial libraries

- Next generation sequencing (NGS) has recently emerged as a new method for the characterization of high throughput immunoglobulin (IG) or antibody immune repertoires both in vivo and in vitro
- A double challenge remains for the NGS sequencing of single chain Fragment variable (scFv) from combinatorial libraries: firstly, the scFv length is > 800 bp, owing to the presence of two variable domains (VH and VL) associated by a peptidic linker and secondly
- Using IMGT/HighV-QUEST with the novel functionality for scFv implemented in IMGT/V-QUEST allowed the analysis and characterization of the association of the two V domains in ~450,000 NGS scFv reads from a selected combinatorial library

Marie-Paule Lefranc, Professor Emeritus, **University of Montpellier**

Insights from native mass spectrometry and ion-mobility mass spectrometry for antibody and antibody-based product characterization

- Native MS and its hyphenation to size exclusion chromatography for mAbs analysis
- Ion-mobility MS for conformational characterization
- Intact mAb analysis

Sarah Cianferani, Head of the BioOrganic Mass Spectrometry Laboratory, CNRS UMR7178, **University of Strasbourg**

13:25

NETWORKING LUNCH

LOOKING TOWARDS THE FUTURE

Chaired by: **Alain Beck,** Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

14:25

Bispecifics - different modalities of drug delivery systems

Eric Hughes, Global Development Franchise Head, Immunology & Dermatology Franchise, **Novartis**

14:45

Next generation bispecific antibodies

- Bispecific Antibodies: from early concepts to drugs
- 20 years (Coloma & Morrison 1997) of recombinant bsAb concepts - why did it take so long?
- Diversity of formats - must have or nice to have?
- BsAb drugs and bsAbs in clinical development
- What comes next?

Ulrich Brinkmann, Scientific Director, Roche Pharma Research & Early Development, **Roche Innovation Centre Munich**

EUROPEAN ANTIBODY CONGRESS AGENDA DAY 3 – THURSDAY 2 NOVEMBER 2017

15:05	**Novel snakebite antivenoms based on oligoclonal recombinant antibodies** • Snakebite - the world's most neglected tropical disease • The use of toxicovenomics (functional venom proteomics) to identify medically relevant snake venom toxins • The use of phage display for discovery of human antibodies capable of neutralizing snake toxins • Manufacturing perspectives for recombinant antivenoms **Andreas Hougaard Laustsen,** Postdoctoral Fellow, Tropical Pharmacology Lab, **Technical University of Denmark**
15:25	**Antibodies to watch in 2018** • A new record (14) for recombinant antibody products granted first marketing approvals may be set in 2017. These products, and those that might be granted approvals in 2018, will be identified. • Antibody therapeutics in Phase 3 clinical studies will be discussed, and those likely to move to regulatory review in 2018 will be noted. • New data on antibody therapeutics development metrics, including clinical phase transition and approval success rates, will be presented. **Janice Reichert,** Executive Director, **The Antibody Society;** Editor-in-Chief, **mABs**
15:45	Chair's closing remarks **Alain Beck,** Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**
15:55	Closing remarks from Terrapinn **Joan Shutt,** Conference Manager, **European Antibody Congress 2017, World Immunotherapy Congress 2017**
16:00	END OF CONGRESS – SEE YOU IN 2018!

Want to get involved? Register your place today at **terrapinn.com/antibody17**
See the website for the most up to date agenda

"IT WAS A GREAT CONGRESS WITH INTERESTING SPEAKERS AND CUTTING EDGE RESEARCH. THERE WAS AMPLE TIME FOR NETWORKING AND A GOOD ATMOSPHERE TO PROMOTE THIS. TIME KEEPING WAS GOOD. FOOD AND VENUE WAS EXCELLENT. I WILL BE BACK NEXT YEAR."

HEAD OF PROTEIN PRODUCTION AND CHARACTERISATION | **MRC TECHNOLOGY** (EUROPEAN ANTIBODY CONGRESS 2017)

WORLD IMMUNOTHERAPY CONGRESS AGENDA DAY 1 – TUESDAY 31 OCTOBER 2017

08:00 Registration opens

08:50 Conference doors open

08:55 Welcome from Terrapinn
Joan Shutt, Conference Manager, **European Antibody Congress, World Immunotherapy Congress 2017**

OPENING KEYNOTES – ANTIBODIES AND IMMUNOTHERAPY

09:00 Chair's opening remarks
Alain Beck, Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

09:05 **Keynote: Combination strategies in immuno-oncology: the future is now**
- First generation immunotherapies highlight the promise of harnessing the immune system to target cancer, but most patients do not receive durable benefit
- The complexity of the immune system and cancer interphase necessitates the development of combination therapies
- Development of rational combination therapies requires deep understanding of both the disease and the immunological landscape of patients

Michael Kalos, Chief Scientific Officer, ImmunoOncology, Lilly Research Laboratories, **Eli Lilly and Company**

09:30 **Keynote: Anti PD-1 antibody therapy – a broad spectrum anticancer monotherapy and a backbone in combination therapy**
- A biologically informed screening phase 2 program has identified broad spectrum monotherapy activity
- Pivotal trials have led to an expanding list of approved monotherapy indications
- Biomarker research is aimed at identifying those who benefit maximally from monotherapy and those who might be studied with biologically informed combination therapies
- An ever-expanding number of highly active combinations are being advanced

Roy Baynes, Senior Vice President & Head, Global Clinical Development, Chief Medical Officer, **MSD**

09:55 **Keynote: Combination therapies – the next frontier**
Puja Sapra, Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research, **Pfizer Worldwide Research and Development**

10:35 NETWORKING REFRESHMENT BREAK

11:35 **PLENARY ROUND TABLE DISCUSSION SESSION**
9 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.

TABLE 1
Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, pAbs
Alain Beck, Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

TABLE 2
Providing precision histopathology for discovery and development
Jeremy Clarke, Director of Commercial Development, **Asterand Biosciences & Lee Dawson,** Scientist, **Asterand Biosciences**

TABLE 3
Assessing off-target liabilities of biotherapeutics
Jim Freeth, Managing Director, **Retrogenix**

TABLE 4
Strategies for tackling cancer
Joern Schmitz, Head, Department of Immunotherapy, **Fraunhofer IME**

TABLE 5
Taking your formats to market
Speaker slot available

TABLE 6
Combination therapy
Speaker slot available

TABLE 7
Immunotherapy for solid tumours
Speaker slot available

TABLE 8
Biomarkers
Speaker slot available

TABLE 9
Preclinical models
Speaker slot available

12:20 **SPEED NETWORKING**
A fun, exciting and effective way to make a lot of initial connections
(in a very different environment from the standard business networking meetings).

WORLD IMMUNOTHERAPY CONGRESS AGENDA DAY 1 – TUESDAY 31 OCTOBER 2017

12:35 NETWORKING REFRESHMENT BREAK

IMMUNE CHECKPOINT INHIBITORS
Chaired by: **Joern Schmitz,** Head, Department of Immunotherapy, **Fraunhofer IME**

14:10 **Development and characterization of Anti-TIGIT antibody for treatment of solid cancers**
- Anti-TIGIT antibody identified by rabbit MAP Trap platform technology was able to block PVR and PVRL2 ligand binding and inhibit TIGIT signaling
- Anti-TIGIT antibody induced tumor specific T-cell response and reduced Treg's suppression, leading to tumor growth suppression and generation of long-term immunological memory against tumors
- Anti-TIGIT can be combines with other ICIs for enhanced anti-tumor activity

Angie Park, Senior Director, Immunotherapy, **OncoMed Pharmaceuticals**

14:30 **Antibody-cytokine fusions for cancer therapy**
- Antibody fusions to IL2 and to TNF
- From the bench to Phase III clinical trials
- Combination therapy opportunities: emerging clinical data
- Splice isoforms of fibronectin and of tenascin-C as targets
- New developments towards second-generation immunocytokines

Dario Neri, Founder, **Philogen;** Professor of Chemistry and Applied Biology, **Swiss Federal Institute of Technology Zurich**

14:50 **Development of innate cell engagers for effective anti-tumor targeting**
- Affimed develops tetravalent, bispecific immuno-engagers for tumor-targeting of T-cells and NK-cells based on proprietary scaffolds and engager domains
- Potency and efficacy of several immuno-engagers are currently being evaluated in clinical mono and combination trials
- Recent developments from our NK-cell engager platform demonstrating superior efficacy over conventional Fc-based approaches will be presented

Martin Treder, Chief Scientific Officer, **Affimed**

15:10 **Targeting immune checkpoints with humabody VH therapeutics**
- Crescendo Biologics develops Humabody VH products, small highly adaptable and flexible proteins which can be developed into differentiated therapeutics
- I will give an overview of Crescendo's approach to developing Immune checkpoint inhibitors and products in immuno oncology
- I will describe development of a BiParatopic Humabody targeting the checkpoint molecule PD-1

James Legg, VP Research and Development, **Crescendo Biologics**

15:30 NETWORKING BREAK

16:30 **OPN-305, a first in class toll like receptor 2 (TLR2) antibody inhibitor**
- TLR2 is a key structure of the innate immune system and one of the main initiators and propagators of inflammation
- OPN-305 is a first in class TLR2 antagonist and anti-inflammatory compound with a unique mode of action
- The TLR2 system is associated and involved with a number of major human diseases:
- (cancer, ischemia reperfusion injury, and autoimmune diseases, among others)
- Pre-clinical and clinical data supports a strong value proposition in oncology
- TLR2 seems to play a major role in the function of tumor dendritic and T regulatory cells pointing to an immune-modulatory role

Martin Welschof, Chief Executive Officer, **Opsona Therapeutics**

16:50 **Innovative solutions for immuno-oncology drug discovery**
- Bespoke immunoassays for target validation, mode-of-action studies and combination immunotherapy design
- In vitro and in vivo tumour-killing and immune response profiling
- Advanced multiplex histology for visualisation and co-localisation of targets

Steve Anderton, Chief Scientific Officer, **Aquila BioMedical**

17:10 **Costimulatory T-Cell engagement by the 4-1BB/HER2 bispecific PRS-343 for tumor localized activation of the immune system**
- Generation of the 4-1BB/HER2 bispecific, PRS-343
- In vitro and in vivo characterisation of PRS-343
- IND enabling studies to support clinical evaluation of PRS-343

Shane Olwill, Head of Immuno-Oncology**, Pieris Pharmaceuticals**

17:30	**The CD47-SIRPa axis as an innate immune checkpoint in cancer** • Immune cell-mediated destruction of antibody-opsonized cancer cells is resticted by CD47-SIRPa interactions. • Mechanistic insights • Applicability for improving antibody therapy in cancer **Timo K. Van den Berg,** Professor of Immunotherapy, **Sanquin Research and Landsteiner Laboratory**
17:50	**TACTI-mel, two ACTive immunotherapies in melanoma: combination of an APC activator (IMP321 or LAG-3Ig) with Pembrolizumab** • Enhance immune response by targeting LAG-3 • Understand the rationale for combining an Antigen Presenting Cell (APC) activator, LAG-3Ig, with an Immune Checkpoint Inhibitor (ICI), pembrolizumab: in vitro and in vivo preclinical data • Evaluation of the combination in metastatic melanoma (TACTI-mel phase I trial) **Frédéric Triebel,** Chief Scientific Officer, Chief Medical Officer, **Prima BioMed**
18:10	Chair's closing remarks **Joern Schmitz,** Head, Department of Immunotherapy, **Fraunhofer IME**
18:15	OFFSITE NETWORKING DRINKS

Want to get involved? Register your place today at **terrapinn.com/immunotherapy17**
See the website for the most up to date agenda

WORLD IMMUNOTHERAPY CONGRESS AGENDA DAY 2 – WEDNESDAY 1 NOVEMBER 2017

08:00 Registration opens

08:50 Conference doors open

08:55 Welcome from Terrapinn
Joan Shutt, Conference Manager, **European Antibody Congress, World Immunotherapy Congress 2017**

STRATEGIES FOR ONCOLOGY

09:00 Chair's opening remarks
Alain Vertes, Managing Director, **NxR Biotechnologies**

09:30 **Panel: Oncology strategies across pharma**
- High level pharma companies come together to discuss their strategies for tackling cancer
- Each company will give a 5-minute presentation on their strategy, and a fire side discussion on oncology focused strategies will follow
- Strategies will cover cytotherapy, checkpoint inhibitors, combination therapy, sequential therapy, approaches to solid tumours, treatments and diagnostics

Moderator: Alain Vertes, Managing Director, **NxR Biotechnologies**
Michael DeRidder, Senior Director, Early Pipeline Commercial Strategy, **Oncology Cell Therapy, GSK**
Christian Rommel, Global Head of Oncology Discovery**, Roche**
Puja Sapra, Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research, **Pfizer Worldwide Research and Development**
Roy Baynes, Senior Vice President & Head, Global Clinical Development, **Chief Medical Officer, MSD**
Michael Kalos, Chief Scientific Officer, ImmunoOncology, Lilly Research Laboratories, **Eli Lilly and Company**

10:25 NETWORKING BREAK

CELL THERAPY

Chaired by: **Alfonso Quintas,** Head of Clinical Research, **Cell Therapies Unit, GSK**

11:25 **Antibody Coupled T-cell Receptor (ACTR): a universal approach to cell therapy for cancer**
- T-cells expressing a chimeric receptor comprising the ectodomain of CD16 together with costimulatory and TCR signalling domains exert powerful cytotoxicity against tumor cells when combined with tumor-targeting monoclonal antibodies.
- By separating tumor cell targeting (via the antibody) from tumor cell killing (via the engineered T-cell), ACTR therapy can be precisely controlled — potentially enhancing its safety and efficacy relative to alternative cell-based approaches.
- Unum is leveraging a wide range of existing antibodies to build a broad pipeline of novel T-cell + antibody combination therapies.

Seth Ettenberg, Chief Scientific Officer, **Unum Therapeutics**

11:45 **Off the shelf engineered NK cells based on the NK-92 platform**
- Update on clinical trial activities with aNK
- haNK cells expressing the high affinity Fc-Receptor for combination therapy with mAbs
- taNK cells engineered to express CARs for neo-epitopes
- Augmenting NK activity with IL-15 super-agonist Altor 803
- Optimizing NK target activity through CRISR based gene manipulation

Hans G. Klingemann, Vice President, **Research & Development, NantKwest**

12:05 **Next generation CAR T cells – Define the concept of CAR T cell therapy for cancer.**
- Recognize barriers to CAR T cell therapy of cancer including T cell persistence, antigen escape, and the immune suppressive tumour microenvironment
- Recognize novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armoured CAR T cell designs may bridge the gap from liquid to solid tumours

Renier Brentjens, Director, Cellular Therapeutics, **Memorial Sloane Kettering Cancer Center**

12:25 **T-cell receptor engineered T-cells as cancer therapeutics**
- Provide an overview of the evolution of TCR-based gene therapy
- Review mechanism of avidity enhancement of TCRs for optimal clinical safety and antitumor activity
- Review clinical results of NY-ESO TCR in advanced sarcoma

Rafael Amado, Chief Medical Officer, **Adaptimmune**

12:45	**TCR T cell therapy in solid tumors** • CAR T cell therapy directed against CD19 has shown remarkable activity in B cell malignancies • However, results have not yet been replicated in solid tumors • High affinity T cell receptor-based adoptive T cell therapy is emerging as an important approach for the treatment of solid tumors **Alfonso Quintas,** Head of Clinical Research, Cell Therapies Unit, **GSK**
13:00	NETWORKING LUNCH
14:35	**CAR-T 2.0 - universal allogeneic, off-the-shelf, CAR-T programs entering the clinic** • First off-the-shelf CAR-T cancer therapy in clinical trials • Using TALEN® to engineer T-cells to target CD123 • Manufacturing T-cell therapy in large scale using cells from donors **André Choulika,** CEO, **Cellectis**
14:55	**NK receptors and CAR T cell therapy: combining innate and adaptive immunity for the immunotherapy of cancer** • CAR T cells exploiting the natural killer receptor NKG2D (NKR2) provide a broad spectrum of tumor indications that can be targeted by one generic vector. • Pre-clinical studies of NKR2 CAR T cells suggest potent anti-tumor activity employing both direct and indirect effector mechanisms of action. • Initial clinical trials carried out in the US suggest a good safety profile at low cell doses and some hints of clinical activity. • A large US and EU based phase I clinical trial is currently testing NKR2 CAR T cell therapy in haematological and solid tumor indications. **David Gilham,** Vice President of Research & Development, **Celyad**
15:15	**Chimeric Antigen Receptor (CAR) vehicles for adoptive cell therapy in solid tumours** • CAR expressing T cells and tumour infiltrating lymphocytes targeting solid tumours • Differences between peripheral and tumour infiltrating lymphocytes • Strategies for improvement of adoptive cell therapy in solid tumours **Milena Kalaitsidou,** Postdoctoral Research Associate, University of Manchester, **GSK**
15:35	**Innovation gaps in the automation of cell-based therapy bioprocessing and overall supply chain models** **James Smith,** Research Associate, **Casmi**
15:55	NETWORKING BREAK
17:00	**Preclinical toxicology within immune-oncology and cell therapy** **Peter Ulrich,** Safety Assessment Expert, **Novartis Institutes for BioMedical Research**
17:20	**TIL focused adoptive cell therapy** **Robert Hawkins,** CEO and Co-founder, **Cellular Therapeutics,** CRUK Chair of Medical Oncology, **The University of Manchester**
17:40	Chair's closing remarks **Alfonso Quintas,** Head of Clinical Research, Cell Therapies Unit, **GSK**
17:45	ONSITE NETWORKING DRINKS
	POSTER PRESENTATION SESSION Posters allow for pharma, biotech and academia to present previously unpublished work. Taking place during the networking drinks on day two of the congress, it will be possible for poster contributors to answer questions and gain feedback.

Want to get involved? Register your place today at **terrapinn.com/immunotherapy17**
See the website for the most up to date agenda

WORLD IMMUNOTHERAPY CONGRESS AGENDA DAY 3 – THURSDAY 2 NOVEMBER 2017

08:00 Registration opens

08:50 Conference doors open

DAY 3 PLENARY SESSION – WORLD LEADING RESEARCH

09:00 Chair's opening remarks

09:05 **Keynote: Bicycles - a paradigm shift in pharmaceutical drugs?**
- New platform based on repertoire technology
- Peptide conjugates with toxic drugs for treatment of cancer

Sir Gregory Winter, Master of Trinity, **Cambridge University,** Founder and Co-Director, **Bicycle Therapeutics**

09:30 **Keynote: Future Biologics: Exploiting the opportunities for protein engineering**
- Future biologics need to open areas of application that expand on today's possibilities. This will be illustrated in several key areas
- The possibility of engineering geometry can be used to exert extremely strong effects on receptor signalling, such as a pan-HER inhibition
- Intracellular targets may gradually come within reach. Using systems inspired by engineered bacterial toxins (3), levels can now be reached which are much higher than with positively charged peptides, and more importantly, allow cell-specific uptake
- Viral delivery may open new avenues to administer cocktails of therapeutic proteins in a localized manner, not by creating replication-proficient "oncolytic" viruses, but instead by engineering viruses, able to target predesigned cell types (5), which can be used to produce therapeutic proteins in vivo, at locations where they are needed

Andreas Plückthun, Professor of Biochemistry, Director, Department of Biochemistry, **University of Zurich**

09:55 **Keynote: Cancer therapy with antibodies at the interface of biology and chemistry**
- The presentation will encompass two strategies on covalently combining antibodies with small molecules to improve their scope and potency
- One strategy employs homogeneous antibody-drug conjugates that selectively deliver highly toxic small molecules to cancer cells without harming healthy cells
- The other strategy is based on chemically programmed bispecific antibodies that endow cancer-targeting small molecules with the power of cancer immunotherapy

Christoph Rader, Associate Professor, Department of Immunology and Microbiology, **The Scripps Research Institute**

10:20 **Keynote: Immune regulation and the antibody response to HIV-1**
- Many antibodies that have potent activity against HIV-1 have characteristics of autoantibodies
- Infected persons who make those antibodies have Immune system perturbations suggestive of dysregulation
- Understanding the relationship between immune dysregulation and HIV-1 antibody responses may help guide vaccine design

M. Anthony Moody, Associate Professor, Department of Paediatrics, Division of Infectious Diseases, **Duke University Medical Centre**

10:45 NETWORKING BREAK

COMBINATION THERAPY

11:45 **Novel T cell bispecific antibodies for combination therapy of cancer**
- Novel T cell bispecific antibody platform
- Enhancing TCB activity by novel combination therapy approaches

Christian Klein, Head of Oncology Programs, **Roche**

12:05 **Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC) with a novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab**
- CEA CD3 TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody targeting CEA on tumour cells and CD3 on T cells
- In preclinical models, CEA CD3 TCB displays potent anti-tumour activity, leads to increased intra-tumoural T cell infiltration and activation and upregulates PD-1/PD-L1
- I will present data from two ongoing dose-escalation phase I studies, RO6958688 is given as monotherapy i.v. QW or in combination (QW) with atezolizumab 1200 mg Q3W in adult patients with advanced CEA+ solid tumours

Jose Saro, Senior Translational Medicine Leader, **Roche**

12:25 **IMCgp100: From development to the clinic**
- ImmTACTM technology platform to generate high-affinity, bi-specific TCR-molecules
- In vitro pre-clinical package to assess the safety and efficacy profile of IMCgp100 in combination with immune checkpoint inhibitors
- IClinical update on IMCgp100 combination therapies in treating melanoma

Annelise Vuidepot, VP, Head of Oncology Pipeline and Research, **Immunocore**

NOVEL DISCOVERY

12:45

Driving CD8+ T cell responses to mutational neoantigens in tumors – harnessing immunogenic viral vectors

- DNA damage may cause mutations in tumors that can generate new antigens, known as tumor-specific neo-antigens (TSNAs)
- Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
- Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
- The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumor microenvironment

Karin Jooss, Chief Scientific Officer, **Gritstone Oncology**

BIOMARKER DISCOVERY

12:25

Immune monitoring assays for first in class cancer immunotherapy trials

- How to select immune assays for first in class agents
- Case studies of what, how and when
- Challenges with pharmacodynamic and patient selection assays for cancer immunotherapy agents

Sidath Katagampola, Biomarker Development Sciensist, Centre for Drug Development, **Cancer Research UK**

13:25 NETWORKING LUNCH

LOOKING TOWARDS THE FUTURE

Chaired by: **Alain Beck,** Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

14:25

Bispecifics - different modalities of drug delivery systems

Eric Hughes, Global Development Franchise Head, Immunology & Dermatology Franchise, **Novartis**

14:45

Next generation bispecific antibodies

- Bispecific Antibodies: from early concepts to drugs
- 20 years (Coloma & Morrison 1997) of recombinant bsAb concepts - why did it take so long?
- Diversity of formats - must have or nice to have?
- BsAb drugs and bsAbs in clinical development
- What comes next?

Ulrich Brinkmann, Scientific Director, Roche Pharma Research & Early Development, **Roche Innovation Centre Munich**

15:05

Novel snakebite antivenoms based on oligoclonal recombinant antibodies

- Snakebite - the world's most neglected tropical disease
- The use of toxicovenomics (functional venom proteomics) to identify medically relevant snake venom toxins
- The use of phage display for discovery of human antibodies capable of neutralizing snake toxins
- Manufacturing perspectives for recombinant antivenoms

Andreas Hougaard Laustsen, Postdoctoral Fellow, Tropical Pharmacology Lab, **Technical University of Denmark**

15:25

Antibodies to watch in 2018

- A new record (14) for recombinant antibody products granted first marketing approvals may be set in 2017. These products, and those that might be granted approvals in 2018, will be identified.
- Antibody therapeutics in Phase 3 clinical studies will be discussed, and those likely to move to regulatory review in 2018 will be noted.
- New data on antibody therapeutics development metrics, including clinical phase transition and approval success rates, will be presented.

Janice Reichert, Executive Director, **The Antibody Society;** Editor-in-Chief, **mABs**

15:45 Chair's closing remarks

Alain Beck, Senior Director, NBEs Analytical Chemistry, **Pierre Fabre,** Associate Editor, **mAbs**

15:15 Closing remarks from Terrapinn

Joan Shutt, Conference Manager, **European Antibody Congress 2017, World Immunotherapy Congress 2017**

16:00 END OF CONGRESS – SEE YOU IN 2018!

Want to get involved? Register your place today at **terrapinn.com/immunotherapy17**
See the website for the most up to date agenda

THE CONFERENCE AT A GLANCE

31ST OCTOBER	1ST NOVEMBER	2ND NOVEMBER

EUROPEAN ANTIBODY CONGRESS 2017

31ST OCTOBER	1ST NOVEMBER	2ND NOVEMBER
Discover: Armed antibodies • Early discovery and analytics	**Strategies for oncology**	**World leading research keynote session**
Develop: Bispecifics • Preclinical Development • Clinical development	**Discover: Armed antibodies** • Target discovery and biomarkers	**Target distribution** **Novel antibody technologies and future uses**
Moving to phase III and beyond • Regulations • Scale up and tech transfer • Manufacture • commercialisation	**Develop: Bispecifics** • Target discovery and biomarkers	**mAbs**
Regulations and INN • FDA update • EPO update • NN panel discussion	**Develop: Armed antibodies** • Preclinical development • Clinical development	
	CMC and developability	
	Discovery: Bispecifics • Early discovery and analytics • Target discovery and biomarkers	

WORLD IMMUNOTHERAPY CONGRESS 2017

31ST OCTOBER	1ST NOVEMBER	2ND NOVEMBER
Immune checkpoint inhibitors • Discovery • Development	**Strategies for oncology**	**World leading research**
	Cell therapy • T Cell therapy • Engineered NK cells • Next generation CAR T	**Combination therapy**
		Novel discovery
		Biomarker discovery
		Looking towards the future

Want to get involved? Register your place today at **terrapinn.com/antibody17**

THE CONFERENCE AT A GLANCE

31ST OCTOBER	1ST NOVEMBER	2ND NOVEMBER

WORLD BIOSIMILAR CONGRESS EUROPE 2017

How to make Biosimilars a Successful Business
- Opportunities and challenges in bringing future biosimilars to market
- Demonstrating interchangeability
- International stakeholders panel discussion

What are the key new international developments? Ask the regulators!
- EMA
- Danish Medicines Agency

Market access strategies, opportunities and commercial challenges
- Overview of the global market: Trends and opportunities
- From biosimilars to biogenerics – the way to lower treatment costs?
- From biosimilars to biogenerics – the way to lower treatment costs?

Development, Manufacturing & Pharmacovigilance
- Challenges in biosimilar bioanalytical assays and sample processing
- Pharmacovigilence (side effects) and innovative clinical trials
- Safety and efficacy study successes

Biosimilar and Biobetter Development and Clinical Challenges and How to Overcome Them
- The biosimilar market in Brazil
- Addressing the immunogenicity issues for biosimilars: A US perspective
- Dealing with high demand: strategies for post launch operating out of Korea

Development, Manufacturing & Pharmacovigilance
- Multiproduct Biosimilar Development, manufacturing and Commercialization Collaboration for Brazil
- Achieving a manufacturing milestone to reliably

WORLD HPAPI CONGRESS 2017

An industry review: challenges & developments of HPAPI strategies

Interactive workshops
- Industry communication & co-operation
- Risk banding
- Data driven controls
- Investigating confusions around regulation
- How to identify the relevant risks
- Containment and engineering
- Interacting with ADCs
- Effective scaling up
- CMO client relationships

Risk assessments and control banding

Containment and handling

ADC's and new molecules

Case studies
Start-ups and large

Drug safety
- Pharmacovigilence
- Big data

Equipment and facility design

Looking to the future of HPAPIs

2017 SPEAKERS

EUROPEAN ANTIBODY CONGRESS 2017

Ahuva Nissim
Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research
Pfizer Worldwide Research and Development

Alain Beck
Senior Director, NBEs Analytical Chemistry, **Pierre Fabre;**
Associate Editor, **mAbs**

Alain Vertes
Managing Director
NxR Biotechnologies

Andrea Gonzalez-Munoz
Research Associate
MedImmune

Andreas Hougaard Laustsen
Postdoctoral Fellow, Tropical Pharmacology Lab
Technical University of Denmark

Andreas Plückthun
Professor of Biochemistry, Director, Department of Biochemistry
University of Zurich

Carl Webster
Principal Scientist, Antibody Discovery and Protein Engineering
MedImmune

Carla Mouta-Bellum
Attorney
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Carsten Krantz
Drug Metabolism and Pharmacokinetics
Novartis Pharma AG

Christoph Merten
Group Leader Microfluidics
European Molecular Biology Laboratory

Christoph Rader
Associate Professor, Department of Immunology and Microbiology
The Scripps Research Institute

Dario Neri
Founder, **Philogen;**
Professor of Chemistry and Applied Biology, **Swiss Federal Institute of Technology Zurich**

Fabian Richter
Post-Doc
University of Stuttgart

Feng Wang
Principal Investigator, Biology
CaliBR

Frank Walsh
CEO
Ossianix

Guanghui Han
Scientific Manager
Genentech

Hans G. Klingemann
Vice President, Research & Development
NantKwest

Haruki Hasegawa
Principal Scientist, Department of Therapeutic Discovery
Amgen

Janice Reichert
Executive Director, **The Antibody Society;**
Editor-in-Chief, **mABs**

James Legg
VP Research and Development
Crescendo Biologics

Jens Wuerthner
Assistant Vice President, Head of Clinical Development – EU
ADC Therapeutics

Joern Schmitz
Head, Department of Immunotherapy
Fraunhofer IME

John Delaney
Executive Director of Research
Amgen

Jose Saro
Pharma Research and Early Development, Oncology
Roche

Katherine (Kangwen) Deng
Senior Scientist
AbbVie Bioresearch Centre

Lars Linden
Head of Protein Biochemistry
Bayer AG

Lee Dawson
Scientist
Asterand

WORLD
IMMUNOTHERAPY
CONGRESS 2017

2017 SPEAKERS

Alexey Rak
Head of Bio Structure and Biophysics
Sanofi R&D

Alfonso Quintas
Head of Clinical Research, Cell Therapies Unit
GSK

André Choulika
CEO
Cellectis

Andreas Wiesner
Global Product Manager, Cell Culture Media
Sartorius Stedim Biotech

Angie Park
Senior Director, Immunotherapy
OncoMed Pharmaceuticals

Annelise Vuidepot
VP, Head of Oncology Pipeline and Research
Immunocore

Christian Kleusch
Application Scientist Biophysics
Nanotemper

Christian Klein
Head of Oncology Programs
Roche

Christian Rommel
Global Head of Oncology Discovery
Roche

David Gilham
Vice President of Research & Development
Celyad

David Meininger
Chief Business Officer
Trianni

Ezio Bonvini
MD - CSO
Macrogenics

Frédéric Triebel
Chief Scientific Officer, Chief Medical Officer
Prima BioMed

Gregory Winter
Master of Trinity,
Cambridge Universit;
Founder and Co-Director,
Bicycle Therapeutics

Greta Hultqvist
Department of Public Health and Caring Sciences
Uppsala University

Helena Domingues
Examiner
European Patent Office

Hervé Watier
Co-ordinator of the MAbImprove LabEx
University of Tours

Ivan Mascanfroni
Senior Scientist, Immunology Biologics
AbbVie Bioresearch Centre

Jerald Sadoff
Senior Advisor Vaccine Development, Senior Clinical Advisor RSV
Janssen Infectious Diseases and Vaccines

Jeremy Clarke
Director of Commercial Development
Asterand

Joachim Feldwisch
Director of Preclinical Development
Affibody AB

Jim Freeth
Managing Director
Retrogenix

Jiri Kovarik
Senior Research Investigator
Novartis Institutes for Biomedical Research

Karin Jooss
Chief Scientific Officer
Gritstone Oncology

Lutz Jermutus
Senior Director, R&D
MedImmune

M. Anthony Moody
Associate Professor, Department of Paediatrics, Division of Infectious Diseases
Duke University Medical Centre

Marie-Paule Lefranc
Chair of Immunogenetics and Immunoinformatics
University of Montpellier

2017 SPEAKERS

EUROPEAN ANTIBODY CONGRESS 2017

Marjorie Shapiro
Chief of Laboratory of Molecular and Developmental Immunology
FDA

Martin Treder
Chief Scientific Officer
Affimed

Martin Welschof
Chief Executive Officer
Opsona Therapeutics

Mihriban Tuna
Vice President, Drug Discovery
F-Star

Milena Kalaitsidou
Postdoctoral Research Associate
University of Manchester
(In collaboration with **GSK**)

Nicolas Fischer
Head of Research Department
NovImmune SA

Puja Sapra
Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research
Pfizer Worldwide Research and Development

Renier Brentjens
Director, Cellular Therapeutics
Memorial Sloane Kettering Cancer Center

Robert Boyd
Scientific Director
Oxford BioTherapeutics UK

Sarah Cianferani
Head of the BioOrganic Mass Spectrometry Laboratory, CNRS UMR7178
University of Strasbourg

Sidath Katagampola
Biomarker Development Sciensist, Centre for Drug Development
Cancer Research UK

Scott Dylla
CSO
Abbvie Stemcentrx

Steffen Hartmann
Global Head of Developability Assessment, Integrated Biologics Profiling
Novartis

Stewart McNaull
Senior VP, Business Development
KBI Biopharma

Syd Johnson
VP, Antibody Engineering
MacroGenics

Ulf Grawunder
CEO
NBE Therapeutics

Ulrich Brinkmann
Scientific Director, Roche Pharma Research & Early Development
Roche Innovation Centre Munich

Victor Obungu
Victor Obungu
Eli Lilly and Company

Andre Choo
Principal Scientist and Director, Antibody Discovery, Bioprocessing Technology Institute
A*STAR

Anubhav Tripathi
Professor of Bioengineering and Medical Science
Brown University

Eric Hughes
Global Development Franchise Head, Immunology & Dermatology Franchise
Novartis

Michael Kalos
Chief Scientific Officer, ImmunoOncology, Lilly Research Laboratories
Eli Lilly and Company

Mostafa Nakach
Head of Pharmaceutical Engineering
Sanofi

Peter Ulrich
Safety Assessment Expert
Novartis Institutes for BioMedical Research

Volker Schellenberger
President and CEO
Amunix

Want to get involved? Register your place today at **terrapinn.com/antib**

WORLD
IMMUNOTHERAPY
CONGRESS 2017

2017 SPEAKERS

Michael DeRidder
Senior Director, Early Pipeline Commercial Strategy, Oncology Cell Therapy
GSK

Michael Schopperle
Chief Executive Officer
CureMeta

Michael Streit
Senior Director, Clinical Leader Research, Translational Medicine and Early Development, Oncology
Janssen

Oliver Spadiut
Assistant Professor, Integrated Bioprocess Development
TU Wien

Patrick Mehlen
Director of Translational Research, **Centre Léon Bérard;**
Chief Executive Officer,
Netris Pharma

Peter Ellmark
Principal Scientist, Immuno-Oncology
Alligator Bioscience

Roy Baynes
Senior Vice President & Head, Global Clinical Development, Chief Medical Officer
MSD

Sagrario Arias Rivas
Principal Scientist and Project Manager
Batavia Biosciences

Sai Reddy
Assistant Professor
ETH Zurich

Seth Ettenberg
CSO
Unum Therapeutics

Shane Olwill
Head of Immuno-Oncology,
Pieris Pharmaceuticals

Stefan Dübel
Director, Department of Biotechnology
Technnische Universität Braunschweig

Thomas Keating
Senior Director, Biochemistry
Immunogen

Thomas Sandal
VP R&D
Crescendo Biologics

Timo K. Van den Berg
Professor of Immunotherapy
Sanquin Research and Landsteiner Laboratory

Volker Lang
Managing Director
AbCheck

Achta Paraiso Le Bourhis
Associate Director, Global Regulatory CMC Lead
Merck

Alex Kelly
European Business Development Executive
Retrogenix

James Smith
Research Associate
Casmi

Jonathan Davis
Principal Scientist, Protein Engineering
Bristol-Myers Squibb

Lisette Bronswijk
Application Scientist Manager EMEA
PALL ForteBio

Rafael Amado
Chief Medical Officer
Adaptimmune

Robert Hawkins
CEO and Co-founder, Cellular Therapeutics, CRUK Chair of Medical Oncology
The University of Manchester

Steve Anderton
Chief Scientific Officer
Aquila BioMedical

2016 TESTIMONIALS

"Great comprehensive meeting, flawless organisation"

ONCOLOGIST
UNIVERSITY HOSPITAL BASEL
(EUROPEAN ANTIBODY CONGRESS 2016)

"The European Antibody Congress is a must-attend for anyone working in the research and development of antibody-based therapeutics and related biologics. A very high quality meeting at a great conference venue, with excellent talks, networking opportunities and forums for discussing topical industry issues. The cancer immunotherapy track and antibody tracks were excellent, and was spoilt for choice; often wished I could be at two sessions at once!""

BIO-TECHNE
(EUROPEAN ANTIBODY CONGRESS 2016)

"Excellent organisation, interesting talks and good networking opportunities"

GROUP LEADER, INSTITUTE OF CELL BIOLOGY AND IMMUNOLOGY
UNIVERSITY OF STUTTGART
(WORLD IMMUNOTHERAPY CONGRESS 2016)

"This is a good meeting with a strong speaker program, well attended by key figures in the sector"

VP BUSINESS DEVELOPMENT
CMC BIOLOGICS
(EUROPEAN ANTIBODY CONGRESS 2016)

"It was a great congress with interesting speakers and cutting edge research. There was ample time for networking and a good atmosphere to promote this. Time keeping was good, food and venue was excellent.
I will be back next year!"

HEAD OF PROTEIN PRODUCTION AND CHARACTERISATION
MRC TECHNOLOGY
(WORLD IMMUNOTHERAPY CONGRESS 2016)

"The event presented a very comprehensive view of the current status of AB research and development with a good balance between established large corporations, early stage players and service providers, in a relaxed atmosphere with plenty of networking opportunities"

SENIOR DIRECTOR OF BUSINESS DEVELOPMENT
CHEMPARTNER EUROPE
(EUROPEAN ANTIBODY CONGRESS 2016)

"Well attended and excellent scientific quality"

MANAGING DIRECTOR
NXR BIOTECHNOLOGIES
(EUROPEAN ANTIBODY CONGRESS 2016)

"Very diverse conference showcasing many technology platforms"

LONZA
(EUROPEAN ANTIBODY CONGRESS 2016)

"Interesting range and depths of talks"

PRECLINICAL SCIENTIST
CANCER RESEARCH UK
(WORLD IMMUNOTHERAPY CONGRESS 2016)

THE EXHIBITION

WHO ATTENDS

- Heads of Pharma
- Heads of Biotech
  - Heads of governmental and regulatory
  - Research / Academia
  - Healthcare
  - Associations
  - Patient Groups

5	AbCheck
8	Retrogenix
9	Agilent Technologies
10	FortéBio
11	KBI Biopharma
12	JSR Life Sciences
13	CMC Biologics
14	Celerion
15	Multipharma
20	Aldevron
21	Quality Assistance
22	Purolite
23	Envigo
24	Sapidyne Instruments
25	Geneious Biologics
26	NanoTemper
28	Genovis
30	Perkin Elmer
33	Aquilia Biomedical
34	Munit
35	Hereaus
41	MabDesign
42	Batavia Biosciences
43	Discover X
44	Asterand Bioscience
45	BioRad
46	Sartorius Stedim Biotec
49	LFB Biotechnologies
50	Biotechne
52	Fujifilm Diosynth Biotechnologies
53	Novo-Nordisk
54	Bruker Daltonik
56	Maxcyte



As of 22.05.2017

WHO SPONSORS

PLATFORM TECHNOLOGY

CMO

UPSTREAM / DOWNSTREAM

REGULATORY AND BUSINESS STRATEGY CONSULTANTS

BIO-INFORMATICS AND COMPUTATIONAL BIOLOGY

Reserve your stand today. Contact: **Derek** on **+44 (0)207 092 1297** or **derek.cavanagh@terrapinn.com**



SOLD RESERVED AVAILABLE

CRO

EQM

CELL LINE DEVELOPERS

LAW FIRMS

NON-GOVERNMENTAL ORGANISATIONS

EUROPEAN ANTIBODY CONGRESS 2017

SPONSORSHIP AND EXHIBITION PACKAGES

BENEFITS	TITLE	PLATINUM	GOLD	SILVER	ASSOCIATE CONTENT	ASSOCIATE BRANDING	PLATFORM TECHNOLOGY SHOWCASE	INNOVATION ZONE
Keynote Presentation (Opening Session)	1							
Keynote Presentation (Plenary session not opening)		1						
Track Presentation	1	1	1	1			1	
Panel Participation	1	1						
Chair of a a Session	1							
Round Table Host	1	1	1		1			
Exhibition Booth	24 sqm	24 sqm	12 sqm	6 sqm	6 sqm	6sqm		2 sqm
Sponsor Networking Drinks Reception	1							
Access to networking manager	1	1	1	1				
Lanyards						1		
E-Shot to industry database	1							
Delegate Passes	6	6	3	3	2	2	1	1

EUROPEAN ANTIBODY CONGRESS 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD IMMUNOTHERAPY CONGRESS 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD BIOSIMILAR CONGRESS EUROPE 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD HPAPI CONGRESS 2016
Natasha Evans
+44 207 092 1212
natasha.evans@terrapinn.com

Can't find a package that's right for you?
Talk to our team about tailoring something to meet your exact needs.

PLATFORM TECHNOLOGY SHOWCASE

Seeking partnership, investment, licencing or looking to sell your technology? Want to hear about the latest innovative platforms? Looking to invest?

A targeted session exploring the most innovative new platform technologies being developed towards antibody engineering and development will take place.

Antibody drug developers will have the chance to see innovative pitches of new technologies that could help them get their pipeline to the next level.

Five, 20 minute presentations showcasing innovative new platform technologies will take place alongside the main scientific conference to a targeted room of professionals.

Do you have a platform technology? You could be one of the 5 companies who will have the chance to pitch to a biotech and pharma audience.

Hear about the latest pioneering platform technologies: sit in on the pitching session to what is out there and see if you could take your antibody development process to the next level.

Audience Participation: give feedback, ask questions, make connections with innovators and perhaps form a new partnership.

See below for more details on how to get involved to get your technology in front of the right people.

Do you have a platform technology that you want to promote or sell? Are you looking for partnership, investment and licencing from big pharma and biotech companies?

If so, keep reading…

As part of the 3rd Platform Technology Showcase, we are offering you the opportunity to apply for one of five, 20 minute pitching slots available on Wednesday, 1st November 2017. Each pitching slot consists of a 15 minute pitch and 5 minutes for questions from an audience of pharma, biotech and investors.

Want to get involved? Register your place today at **terrapinn.com/antibody17**

IT'S A NETWORKING EVENT

The European Antibody Congress recognizes the importance of networking and offers an experience which allows you to do just that.



ROUNDTABLE DISCUSSIONS

With moderators to lead discussions on key topics, you will take your engagement and learnings to a new level in this interactive and results-driven setting.

NETWORKING RECEPTION

It's not always about the conference sessions. Our themed evening networking drinks receptions both at the conference venue and off-site on days one and two will allow you to unwind with your peers and continue conversations in good company.



SCIENTIFIC POSTERS

Share research with leaders in the antibody sector within the dedicated Scientific Poster session. Posters allow for pharma, biotech and academia to present previously unpublished work. taking place during the networking drinks on day two of the congress, it will be possible for poster contributors to answer questions and gain feedback. Refreshments will be served throughout.

Please see **terrapinn.com/antibody** for further details.

NETWORKING LUNCHES

Our extended lunch periods will provide you with ample time to network between sessions. These lunch formats allow for more opportunities for casual conversations and introductions, without compromising your time attending the conference sessions.



Want to get involved? Register your place today at **terrapinn.com/antibody17**

WHO ATTENDS?

Over 500 delegates will be attending this year from pharma, biotech, clinicians, academics, researchers and start-ups.

Here is a list of the companies who attended last year:

4-Antibody AG | A.L.S. Automated Lab Solutions | AbbVie | AbbVie Bioresearch Center Inc | AbCheck | Affibody AB | Agilent Technologies | Aldevron | Amal Therapeutics | Amgen Research Munich Gmbh| Amt für Wirtschaft und Arbeit | Amunix Inc | anaRIC biologics | Antibody Chain | Asterand Bioscience | AstraZeneca | Aurealis Pharma | Avacta Life Sciences | Avicenna Oncology GmbH | Axenis | Basel Area | Bayer Ag | Bentham Science Publishers | Bio Rad | Bio Rad Abd Serotech Gmbh | BioCanRx | Biognosys Ag | BioLegend Gmbh | BIOMUNEX PHARMACEUTICALS | Bioneer | Bio-Rad Laboratories | Biosave | Bio-Techne | Blood Transfusion Centre of Slovenia | Boehringer Ingelheim | Bucher Biotec AG | Cancer Research UK | Canton of Basel-Stadt | Carbogen Amcis AG | Catalent Pharma Solutions | Celerion | Cellectis | Cellestia Biotech | Cenibra GmbH | Centre d'Immunologie Pierre Fabre | ChargePoint Technology Ltd | ChemoMetec A/S | ChemPartner Europe | Chiome Bioscience, Inc | Chiral Technologies Europe | CMC Biologics | Complix Nv | Compugen Ltd | Covagen AG | Crescendo Biologics Ltd | Crown Bioscience | Abcheck s.r.o. | Ablynx | Abzena | Actelion Pharmaceuticals Ltd | Adaptimmune | CSBJ journal | CureMeta Llc | Development Center for Biotechnology | DiscoveRx Corporation | Dybly Ag | E.T.H. Zurich | Eleven Biotherapeutics | Elsevier | EUCODIS Bioscience GmbH | Eurogentec - Kaneka | Europa Bioproducts | Eurogentec European Molecular Biology Laboratory | European Patent Office | Experimental Cancer Medicine Centres | Network | F. Hoffmann-La Roche Ltd | F.P.S. Food and Pharma Systems Srl | Farmavita Regulanet | FGen GmbH | Finnegan Llp | ForteBio A division of Pall Life Sciences Inc | Fraunhofer Institute for Cell Therapy and | Immunology |Fujifilm Diosynth Biotechnologies | Fujifilm United Kingdom Ltd | GamaMabs | Genentech | Geneva University Hospital | Glenmark Pharmaceuticals SA | Glycotope | HiFiBio | Histalim | Humabs BioMed Sa | Ibis Technologies | Icon Plc | Icosagen Cell Factory Ltd | iDD Biotech | IgC Bio | Immatics Biotechnologies GmbH | Immunocore | Immunogen, Inc | I-Net | Innate Pharma | Inserm Transfert | Institut Pasteur | Institute of Cancer Research | Intellicyt Corp | Iptechex Pharmalicensing | ITALFARMACO S.P.A. | ITRI | Janssen

Want to get involved? Register your place today at **terrapinn.com/antibody17**

REGISTER YOUR PLACE TODAY



The earlier you book the more you'll save.

terrapinn.com/antibody17

Package	05 May	26 May	30 June	21 July	18 August	15 September	13 October	FINAL PRICE
Standard Package	€2090 **SAVE €1205**	€2150 **SAVE €1145**	€2250 **SAVE €1045**	€2395 **SAVE €900**	€2595 **SAVE €700**	€2850 **SAVE €445**	€3095 **SAVE €200**	€3295 **SAVE €0**
Academic	€1315 **SAVE €440**	€1355 **SAVE €400**	€1405 **SAVE €350**	€1455 **SAVE €300**	€1525 **SAVE €230**	€1580 **SAVE €175**	€1670 **SAVE €85**	€1755 **SAVE €0**

BOOK NOW

Register at
terrapinn.com/antibody17
Or call **+44 (0) 207 092 1257**

BRING YOUR TEAM

With three days packed full of great content and networking opportunities, you can't possibly cover it all alone!

Bring your team and get an extra discount.

Call **+44 (0) 207 092 1257**

2017 SPONSORS & EXHIBITORS

Partners

Basel

Gold Sponsors

KBI BIOPHARMA

RETROGENIX™ SPOTTING YOUR TARGET.

FUJIFILM Diosynth biotechnologies

Silver Sponsors

CMC biologics

Lonza

Novo Nordisk Pharmatech A/S

novo nordisk

MaxCyte

Aquila BioMedical

sartorius stedim biotech

forteBIO A Division of Pall Life Sciences

BRUKER

PerkinElmer For the Better

celerion Applied Translational Medicine

Associate Sponsors

FINNEGAN

nanoTEMPER technologies

ASTERAND BIOSCIENCE EXPERTS IN HUMAN TISSUE

BATAVIA biosciences

AB CHECK

SKAN

Exhibitors

Agilent Technologies

++++ ENVIGO

FPS FOOD PHARMA SYSTEMS

geneious biologics

GENOVIS

psl www.powdersystems.com

Heraeus

Purolite Life Sciences

aldevron

QUALITY ASSISTANCE Contract Research Organisation

MABDESIGN

munit WE ARE MICRONIZATION

TRIANNI

biotechne

DiscoverX

BIO-RAD

JSR Life Sciences JSR MATERIALS INNOVATION

Sapidyne Instruments

Want to get involved? Register your place today at **terrapinn.com/antibody17**